SOURCE: Xtalks

Xtalks Webinars

January 06, 2016 07:00 ET

Upcoming Webinar to Examine Combating Emerging and Re-Emerging Infectious Diseases in Clinical Trials by Harnessing Innovative Technologies

TORONTO, ON--(Marketwired - January 06, 2016) - This webinar, taking place on Wednesday, January 20, 2016, will highlight the challenges of emerging and re-emerging infectious diseases such as MTB, HIV, MRSA, and Ebola. It will also provide case studies on how innovative technologies like NGS are utilized to provide a deeper understanding of the pathogen and drug resistance pathways and thus provide better insights into developing diagnostics and therapies that are efficacious against the target pathogen and its resistant variants with improved safety.

The live broadcast will feature presenters from Q2 Solutions, a Quintiles Quest Joint Venture, including Stephen Mortlock, Global Infectious Diseases and Microbiology Liaison (Heston, UK), Ayaskant Pany, Director of Medical and Central Laboratories (South Africa), and Sorika van Niekerk, Senior Director/General Manager of Central Laboratories (South Africa).

The golden age of antibiotics proved to be a short-lived one as there is now sufficient evidence to show that one of the most important emerging public health threats is that of large-scale dissemination of multi-resistant pathogens in the hospital environment, the community, and the wider environment. But how has mankind got into this predicament? In developed countries, one leading factor is the over-prescription by physicians of antimicrobials, particularly antibiotics, even in the absence of appropriate indications. Such inappropriate physician practices are often fostered by diagnostic uncertainty, lack of opportunity for patient follow-up, lack of knowledge regarding optimal therapies, and patient demand. In many developing countries, problems typically arise because antimicrobial agents are readily available and can be purchased as a commodity without the advice or prescription of a physician or other trained health care provider.

Bacteria and other pathogens have always evolved so that they can resist the new drugs that medicine has used to combat them. Resistance has increasingly become a problem in recent years because the pace at which we are discovering novel antibiotics has slowed drastically, while antibiotic use is rising. And it is not just a problem confined to bacteria, but all microbes that have the potential to mutate and render our drugs ineffective. The great strides forward made over the past few decades to manage Tuberculosis (MTB) and HIV could be reversed, with these diseases once again spiraling out of control. Emerging Infectious diseases represent a growing risk to global human health. The goal of drug development programs is to develop diagnostics and therapies that are efficacious against the pathogen and its resistant variants. For example, microbes and the mechanisms by which they cause disease can now be quickly characterized through rapid genomic sequencing, proteomics, epigenomics, and other tools. Genomics technology is also being applied diagnostically, enhancing the ability to detect microbes at the point of care and to track their spread within human populations. Advances in structural biology, including x-ray crystallography and cryo-electron microscopy, have allowed investigators to characterize the conformations of microbial proteins in detail. An improved understanding of host-pathogen interactions and microbial protein function have led to more rational drug designs, resulting in important therapeutic advances against microbial infection including HIV and HCV. In addition, new platforms for vaccine and antibiotic design, such as nanoparticles and virus-like particles, have opened avenues for vaccine and antibiotic development.

For more information or to register for this free webinar visit: Combating Emerging and Re-emerging Infectious Diseases in Clinical Trials by Harnessing Innovative Technologies.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com.

For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx.

Image Available: http://www.marketwire.com/library/MwGo/2016/1/5/11G077317/Images/Q2Solutions_descriptor_rgb-633545423925.jpg

Contact Information